Cornelia Glaser

Identification of a treatment-responsive monocyte population as a biomarker for active, untreated giant cell arteritis

Markus Zeisbrich, Roman Sankowski, Cornelia Glaser, Nils Venhoff et autres

Introduction: Giant cell arteritis (GCA) is an inflammatory vasculitis of large and medium-sized vessels in individuals over the age of 50 years. To date, no disease-specific autoantibodies or laboratory biomarkers have been identified. Immunologically, GCA is characterized by a pronounced acute phase …

de (code pays fourni par la source)

Schwangerschaftsausgänge bei Frauen mit autoinflammatorischen Erkrankungen – Daten aus dem Rhekiss‑Register

Isabell Haase, Ann‐Christin Pecher, Anja Strangfeld, T. Rudi et autres

Einleitung: Autoinflammatorische Erkrankungen (AID) wie das familiäre Mittelmeerfieber (FMF), die adult-onset Still-Erkrankung (AOSD) und weitere periodische Fiebersyndrome sind durch eine Dysregulation der angeborenen Immunität mit rezidivierender systemischer Entzündung gekennzeichnet. [zum vollständigen Text gelangen Sie über die oben angegebene URL]

de (code pays fourni par la source)

Elevated IL-10 is Linked With the Expansion of T-bethighCD21low B Cells in Patients With Common Variable Immunodeficiency

Victoria Cousin, Anna Graumann, Valerie Geiger, David Sökler et autres

Abstract Common variable immunodeficiency (CVID) is frequently complicated by autoimmune and inflammatory manifestations associated with profound immune dysregulation (CVIDc), including expansion of T-bet high CD21 low B cells (CD21 low B cells). Elevated serum IL-10 levels have repeatedly been reported in CVIDc, …

de, it, es, cn (code pays fourni par la source)

Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.

Megan E B Clowse, Radboud J E M Dolhain, Stephanie Finzel, Frauke Förger et autres

Introduction Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab …

us (code pays fourni par la source)

We, Myself and AI: On the Benefits of Combining AI and Cooperative Planning for Writing Motivation

Maik Philipp, Cornelia Glaser, Valentin Unger, Mirjam Wolfangel

Presented

Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study

Megan E. B. Clowse, Radboud J. E. M. Dolhain, Stephanie Finzel, Frauke Förger et autres

INTRODUCTION: Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab …

us, nl, de, ch, es, be (code pays fourni par la source)

Association of ADHD symptoms, pain, and tics with anti-thalamus antibodies in cerebrospinal fluid

Dominique Endres, Katharina von Zedtwitz, Alexander Rau, Bernd Feige et autres

Introduction Complex mixed presentations of severe mental disorders (SMD) with treatment resistance pose major challenges in clinical practice. The role of novel neuronal antibodies in cerebrospinal fluid (CSF) is largely unexamined in this context. Methods A well-studied paradigmatic case of a 36-year-old …

de (code pays fourni par la source)

POS1327 COMPARISON OF PREGNANCY CHARACTERISTICS AND OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN TWO DIFFERENT GERMAN DATA SOURCES: A NATIONWIDE PREGNANCY REGISTER AND A CLAIMS DATA BASE

Yvette Meißner, Johanna Callhoff, T. Rudi, Carlo Veltri et autres

Background: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease with female predominance and disease onset in reproductive age. Pregnancies in women with SLE are classified as high-risk since they are associated with more frequent maternal and fetal complications compared to …

de (code pays fourni par la source)

OP0325 LONG-TERM PREVENTION OF RA IN HIGH-RISK INDIVIDUALS AFTER A 6-MONTH PLACEBO-CONTROLLED INTERVENTION WITH ABATACEPT -THE ARIAA TRIAL

Mikkel Østergaard, V. Schönau, Uta Kiltz, Xenofon Baraliakos et autres

Background: A 6-month intervention with abatacept in the ARIAA trial (EUDRA-CT 2014–000555–93) significantly retarded the development of RA compared to placebo in ACPA-positive individuals with joint pain and subclinical inflammation on hand MRI. This inhibitory effect peaked at the end of the …

de, dk, us (code pays fourni par la source)

Rhekiss—The German Register for Child Wish and Pregnancies in Inflammatory Rheumatic Diseases

Anja Strangfeld, Yvette Meißner, Anja Weiß, T. Rudi et autres

In pharmacoepidemiology, robust data are needed to judge the impact of drug treatment on pregnancy, pregnancy outcomes and breast-fed infants. As pregnant and breastfeeding women are usually excluded from randomised clinical trials, observational studies are required. One of those data sources are …

de (code pays fourni par la source)

POS0888 PHARMACOKINETICS OF CERTOLIZUMAB PEGOL IN PREGNANCY: RESULTS FROM THE OPEN-LABEL, PHASE 1B CHERISH STUDY

Megan E. B. Clowse, Radboud J. E. M. Dolhain, Stephanie Finzel, Frauke Förger et autres

us, nl, de, ch, es, gb, be (code pays fourni par la source)

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

Jürgen Rech, Koray Taşçılar, Melanie Hagen, Arnd Kleyer et autres

de, ch, at, es, cz, it, dk (code pays fourni par la source)